BioSpace News Archive

Men Experience Higher Levels of Stress as Crisis Continues

[21-July-2020] OTTAWA, ON , July 21, 2020 /CNW/ - Health Canada is advising Canadians that the following hand sanitizers made with ethanol or denaturants that are not acceptable for use in hand sanitizers, may pose health risks. Denaturants are added to ethanol to make it unfit for human consumption and, therefore, to avoid the unintentional ingestion of hand sanitizers (particularly by children

Today, the Washington State Department of Health, UW Medicine and the Paul G. Allen Family Foundation announced the launch of a major study to determine the percentage of Washingtonians who have been infected by COVID-19.

Carmel-based PathogenX, a medical device company which develops, manufactures, and distributes proprietary technology designed to dramatically simplify the process of medical waste disposal, today announced that full national distribution throughout the United States and Canada is now available for its unique, double-batch, on-site sterilization device, the PX2.

The Government of Canada is working to ensure that essential service organizations have access to the key supplies that they need to keep their members safe during COVID-19 as our economy reopens.

Elizabeth Lee-Lewandrowski, Ph.D., MPH, a national key opinion leader on tick-borne diseases, will discuss the findings of a national seven-year study on Lyme disease testing on a webinar she will be conducting on Thursday, July 30.

Shockwave Medical, Inc. announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020.

Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously announced underwritten public offering of 8,385,417 shares of its common stock at a price to the public of $24.00 per share.

Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the closing of its global offering of an aggregate of 11,000,000 new ordinary shares,

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the closings of an underwritten public offering, the full exercise of the underwriter’s over-allotment option, and a private placement, for total gross proceeds of approximately $6.2 million, prior to deducting underwriting discounts, placement agent fees, and offering expenses.